Alnylam Pharmaceuticals Inc
LSE:0HD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
D
|
Dollar General Corp
XMUN:7DG
|
US |
|
A
|
Allgeier SE
DUS:AEIN
|
DE |
|
Eastwood Bio-Medical Canada Inc
OTC:EWOOF
|
CA |
|
MEI Pharma Inc
NASDAQ:MEIP
|
US |
|
Aedifica NV
OTC:AEDFF
|
BE |
|
T
|
Truist Financial Corp
DUS:BBK
|
US |
|
H
|
Hitachi Ltd
OTC:HTHIF
|
JP |
|
Pizza Pizza Royalty Corp
TSX:PZA
|
CA |
|
D
|
Datang International Power Generation Co Ltd
OTC:DIPGF
|
CN |
|
S
|
Sociedad Quimica y Minera de Chile SA
XBER:QYM
|
CL |
|
T
|
TopBuild Corp
F:28T
|
US |
|
Compass Minerals International Inc
NYSE:CMP
|
US |
|
F
|
Factset Research Systems Inc
DUS:FA1
|
US |
|
Pepkor Holdings Ltd
OTC:PPKRF
|
ZA |
|
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
US |
|
B
|
Boyd Gaming Corp
XMUN:BO5
|
US |
|
P
|
PepsiCo Inc
F:PEP
|
US |
|
Datatec Ltd
F:DTT
|
ZA |
|
Societe LDC SA
F:LC4
|
FR |
|
M
|
Macy's Inc
DUS:FDO
|
US |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
US |
|
T
|
Tile Shop Holdings Inc
SWB:2TS
|
US |
|
W
|
Willis Towers Watson PLC
XBER:WTY
|
UK |
Wall St Price Targets
0HD2 Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0HD2 is 446.53 USD with a low forecast of 234.11 USD and a high forecast of 583.71 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0HD2's stock price target?
Price Target
446.53
USD
According to Wall Street analysts, the average 1-year price target for 0HD2 is 446.53 USD with a low forecast of 234.11 USD and a high forecast of 583.71 USD.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 8 years is 36%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Net Income over the next 8 years is 41%.
